Cosmo pharmaceuticals

At Cosmo, we are committed to improve peoples lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Investors

Latest News

18 Jun 2024

Cosmo’s oral diagnostic drug Lumeblue® receives approval of New Drug Application in China

Read More
03 Jun 2024

Cosmo to bring real-time AI into intelligent medical devices with NVIDIA IGX

Read More
31 May 2024
AD HOC

Cosmo reports excellent final Full Year 2023 financial results – Increases operating profit guidance for 2024 – Dividend of € 2.00 per share will be proposed at EGM on 5 July 2024

Read More

Upcoming Events

05 Jul 2024

Extraordinary General Meeting

Add to Outlook
24 Jul 2024

Half Year Results 2024

Add to Outlook

Latest presentation

21 Mar 2024
Investor Day Full Year Results 2023

Therapeutic Focus

Cosmo’s therapeutic focus is on the treatment of gastrointestinal diseases (including IBD, colonic infections and colorectal cancer – CRC), increase the effectiveness of endoscopic examinations and to treat persistent skin conditions, like acne, and androgenetic alopecia, that have a long-term physical and emotional impact on lives and self-esteem.

Find out more

Our Mission

To improve people’s lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Find out more

Manufacturing

We provide services related to the production of pharmaceutical products as: assessment of manufacturing processes, technology transfer, evaluation of pharmaceutical product stability, testing and release to the market and drafting of the necessary documentation for pharmaceutical products’ registration.

Find out more